FOLFIRI is a combination chemotherapy treatment that includes three medications: fluorouracil, leucovorin, and irinotecan. It is commonly used to treat various types of gastrointestinal cancers. This combination works by interfering with cancer cell growth and division.

Domvanalimab is an experimental immunotherapy medication that targets TIGIT, a protein found on immune cells. It works by helping the immune system recognize and fight cancer cells more effectively.

Zimberelimab is an immunotherapy medication that blocks PD-1, a protein that can prevent T-cells (immune cells) from attacking cancer cells. By blocking PD-1, this medication helps the immune system to better recognize and destroy cancer cells.

The combination of these medications is being studied to determine if adding immunotherapy (Domvanalimab and Zimberelimab) to standard chemotherapy (FOLFIRI) can improve outcomes for patients with advanced gastric or gastro-esophageal junction cancer.

Stomach cancer – A disease that begins when cancer cells form in the inner lining of the stomach. The cancer typically develops slowly over many years, starting with pre-cancerous changes in the stomach lining. These abnormal cells can grow into the deeper layers of the stomach wall and eventually spread to other parts of the body.

Esophageal cancer – A cancer that develops in the esophagus, the muscular tube that connects the throat to the stomach. The disease begins when cells in the inner layer of the esophagus start growing abnormally. These cells can gradually grow through the wall of the esophagus and spread to other parts of the body.

Gastro-esophageal junction adenocarcinoma – A specific type of cancer that develops in the area where the esophagus joins the stomach. This cancer starts in the glandular cells at this junction point. The disease begins in the inner layer of this area and can grow outward through the other layers of tissue.